Northwest Biotherapeutics (NWBO) Amortization of Deferred Charges (2014 - 2026)

Northwest Biotherapeutics' Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $76000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 18.75% year-over-year to $76000.0 in Q1 2026; TTM through Mar 2026 was $285000.0, a 0.7% decrease from a year earlier, with the FY2025 full-year figure at $273000.0, down 9.0% from the prior year.
• Amortization of Deferred Charges rose to $76000.0 in Q1 2026 per NWBO's latest filing, from $73000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $82000.0 in Q2 2024 and bottomed at $63000.0 in Q3 2022.
• The 5-year median for Amortization of Deferred Charges is $71000.0 (2023), against an average of $71000.0.
• Across the five-year window, Amortization of Deferred Charges slipped 19.51% in 2025 and advanced 18.75% in 2026, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $63000.0 in 2022, then rose by 15.87% to $73000.0 in 2023, then dropped by 12.33% to $64000.0 in 2024, then increased by 14.06% to $73000.0 in 2025, then grew by 4.11% to $76000.0 in 2026.
• Per Business Quant, the three latest NWBO Amortization of Deferred Charges figures stand at $76000.0 (Q1 2026), $73000.0 (Q4 2025), and $70000.0 (Q3 2025).